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The management of resectable rectal cancer continues to be guided by clinical trials and advances in technique.
Although surgical advances including total mesorectal excision continue to decrease rates of local recurrence, the
management of locally advanced disease (T3-T4 or N+) benefits from a multimodality approach including
neoadjuvant concomitant chemotherapy and radiation. Circumferential resection margin, which can be determined
preoperatively via MRI, is prognostic. Toxicity associated with radiation therapy is decreased by placing the patient
in the prone position on a belly board, however for patients who cannot tolerate prone positioning, IMRT
decreases the volume of normal tissue irradiated. The use of IMRT requires knowledge of the patterns of spreads
and anatomy. Clinical trials demonstrate high variability in target delineation without specific guidance
demonstrating the need for peer review and the use of a consensus atlas. Concomitant with radiation, fluorouracil
based chemotherapy remains the standard, and although toxicity is decreased with continuous infusion fluorouracil,
oral capecitabine is non-inferior to the continuous infusion regimen. Additional chemotherapeutic agents, including
oxaliplatin, continue to be investigated, however currently should only be utilized on clinical trials as increased
toxicity and no definitive benefit has been demonstrated in clinical trials.
The ACR Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed
every two years by a multidisciplinary expert panel. The guideline development and review include an extensive
analysis of current medical literature from peer reviewed journals and the application of a well-established
consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the
panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend
imaging or treatment.
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Background
The American Cancer Society estimates there will be
103,170 new cases of colorectal cancer in 2012 with
40,290 of those being located in the rectum [1]. Anato-
mically, the rectum begins above the dentate line, which
marks the cephalad extent of the anal canal, and extends
above the peritoneal reflection to the sigmoid colon. The
location of the rectum deep in the pelvis with its tight
confines complicates surgical resection, leading to an
increased risk of local recurrence with surgical resection
alone. Local and distant recurrence rates after non-total* Correspondence: thomasch@ohsu.edu
2Knight Cancer Institute at Oregon Health and Science University, Portland,
Oregon, US
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© 2012 Jones et al.; Copyright American Collemesorectal excision (TME) surgery alone are as high as
40%-60% [2], thus warranting adjuvant therapy to
improve local/regional control. Clinical trials have inves-
tigated the use of multimodality therapy to decrease the
incidence of both local and distant recurrence. Histori-
cally, after surgical resection adjuvant therapy would be
delivered if high-risk features were discovered upon
pathologic examination of the surgical specimen. Subse-
quent investigation examined the role of neoadjuvant
therapy, and most recently comparisons of these techni-
ques have been published. This document summarizes
the major clinical trials and the role for multimodality
therapy.
In 2004, a randomized trial from Germany was pub-
lished establishing a regimen of preoperative chemora-
diotherapy and surgery followed by additional cycles ofge of Radiology.
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stages T3 or T4, or for node-positive rectal cancer [3].
Other clinical studies from the United States, Europe,
and Asia have also influenced the treatment strategies
for operable rectal cancer, as various approaches using
preoperative or postoperative radiotherapy, with or with-
out chemotherapy, have been examined. A summary of
the major randomized clinical trials spanning the past
several decades is provided below.
Prognostic factors
Overall survival (OS) is most affected by the extent of
disease, with increasing depth of rectal wall penetration
and lymph node involvement being harbingers of worse
outcome. Tumor location appears to be important in
rectal cancer, with low-lying tumors having a greater
propensity for local recurrence. Histological tumor grade
is prognostic, with poorly differentiated tumors having a
worse prognosis. The signet ring cell and mucinous vari-
eties also portend a less favorable outcome. The muci-
nous variety can be visualized via magnetic resonance
imaging (MRI) defined by greater than 50% mucin in the
tumor, and this variety has recently been shown to
respond less favorably to neoadjuvant chemoradiation.
The pathologic circumferential resection margin (CRM)
has been demonstrated to be prognostic, and at least
one retrospective series confirms decreased cancer-
specific survival with a CRM ≤2 mm [4,5]. Additionally,
the ypCRM status (after neoadjuvant chemoradiother-
apy) is a significant risk factor for local recurrence [6].
High-quality surgery with pathological evaluation of
TME specimens is associated with a decreased risk of
local recurrence. A pathological review of specimens
from the Medical Research Council/United Kingdom
(MRC CR07) trial, which required TME, clearly demon-
strates that excellent surgical technique is directly
related to local recurrence [7]. Only 52% of the speci-
mens demonstrated a “good” resection truly in the
mesorectal plane, 34% were found to be “intermediate”
in the intramesorectal plane, and 13% were “poor” invol-
ving the plane of the muscularis propria. The 3-year risk
of local recurrence was directly related to quality of sur-
gery, with high-quality surgery resulting in a lower
recurrence. Importantly, all surgical groups, regardless
of quality of resection, benefitted from neoadjuvant
radiation therapy.
Dose
Preoperatively large radiotherapy portals covering the
tumor, entire mesorectum, and lymph node regions at
risk are typically treated to 45 Gy with a boost deliv-
ered to the tumor and presacral lymph nodes. The
boost dose typically ranges in clinical trials from 5.4
to 9 Gy. The Radiation Therapy Oncology GroupW(RTOGW) conducted a phase II study (R-0012) investi-
gating combined-modality therapy with higher doses
and hyperfractionation [8]. Higher doses were associated
with a similar pathologic complete response (pCR) rate
at the cost of increased grade 3-4 acute toxicity; thus,
the standard remains 50.4 to 54 Gy.
Postoperative radiotherapy with or without
chemotherapy
Several classic trials have examined the use of postopera-
tive irradiation alone or in combination with chemother-
apy; conducted by the Gastrointestinal Tumor Study
Group (GITSG), the North Central Cancer Treatment
Group (NCCTG), and the Norwegian Adjuvant Rectal
Cancer Project Group, radiotherapy delivered with con-
current chemotherapy improved both local control and
survival [9-11]. Subsequently, studies R-01 and R-02 by
the National Surgical Adjuvant Breast and Bowel Project
(NSABP) demonstrated that the role of radiotherapy is
primarily local control in the postoperative setting
[12,13].
The method of administrating chemotherapy appears
to be important in obtaining optimal results. Protracted
venous infusion of 5-fluorouracil (5-FU) was found to be
superior to bolus 5-FU, with a 45%-50% decrease in
hematologic toxicity [14] and is considered to be a stan-
dard adjuvant therapy; more recent studies have investi-
gated alternate means of optimizing chemotherapy [14-
16]. The choice of early versus late radiotherapy with
respect to chemotherapy may also be important accord-
ing to the preliminary results of a recent randomized
study [17] and warrants further investigation. Because
neoadjuvant chemoradiotherapy is superior to post-
operative delivery, in cases where chemoradiation is
clearly indicated, cT3-4 or N+neoadjuvant delivery is
preferred. (See Table 1 and Table 2.)
Preoperative radiotherapy with or without chemotherapy
Exploring the role of preoperative radiotherapy alone
(25 Gy in 5 fractions), a Swedish trial showed improve-
ments in both local control and survival that persisted at
13 years of follow-up [18,19]. Late toxicity with this
hypofractionated regimen is substantial and includes an
increased risk of small-bowel obstruction, abdominal
pain, diarrhea, bleeding, and fistula formation [20,21].
Both the MRC CR07 trial and the Dutch Colorectal
Cancer Group (CKVO 95-04) investigated the role of
radiation therapy with high-quality TME surgery. The
Dutch study randomized 1,805 eligible patients to either
surgery alone or short course radiation therapy (5 x 5
Gy) followed by surgery, and concluded that the addition
of radiation significantly decreases the rate of local
recurrence at 2 years even with high-quality surgery
(P < 0.001) [22]. The MRC CR07 study attempted to
Table 1 70-year-old woman staged with endorectal
ultrasound (EUS), a T2NX rectal cancer at 3 cm from
verge, final pathology was T3N1 status post
abdominoperineal resection (APR), KPS ≥70
Treatment Rating Comments
Treatment Options
RT + chemotherapy 9
RT alone 2
Chemotherapy alone 2
If RT + Chemo: RT Dose to Primary
45 Gy/1.8 Gy 6
50.4 Gy/1.8 Gy 9
54 Gy/1.8 Gy 8 If small bowel is
completely excluded
after 50.4 Gy.




Patient prone 9 Unless physically





9 Not mandated with
CT simulation.
Patient immobilized 9
Use belly board 9 Only needed if prone.
Perineal scar marker 9
Bladder full at simulation 7
If RT + Chemo: RT Volume
L5/S1 pelvis to include
perineal scar
9




3 or 4 field with photons 9 Depending on clinical
situation.
AP/PA 1
3 field with electron
boost to perineum
3
4 field with electron
boost to perineum
3
IMRT 6 May be appropriate
depending on the
clinical situation on a
case-by-case basis.
Enrollment in a clinical
trial preferred.
Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9
Usually appropriate.
Table 2 70-year-old woman staged with EUS, aT2NX
rectal cancer with caudal extent located 9 cm from verge,
final pathology was T3N1 status post low anterior
resection (LAR), KPS ≥70
Treatment Rating Comments
Treatment Options
RT + chemotherapy 9
RT alone 2
Chemotherapy alone 2
If RT + Chemo: RT Dose to Primary
45 Gy/1.8 Gy 6
50.4 Gy/1.8 Gy 9
54 Gy/1.8 Gy 8 If small bowel is
completely excluded
after 50.4 Gy.




Patient prone 9 Unless physically unable.




9 Not mandated with
CT simulation.
Patient immobilized 9
Use belly board 9 Only needed if prone.
Anal marker 9
Bladder full at simulation 7
If RT + Chemo: RT Volume
L5/S1 pelvis to
include anal marker
2 CT simulation preferred.
Use CT to ensure margin
on inferior extent of
tumor. Technically,
the field should extend
2-3 cm below the
anastomosis on the CT.
L5/S1 pelvis to bottom
of ischial tuberosity
5 CT simulation preferred.
Bony landmark is an
approximation. Use CT
to ensure margin on
inferior extent of tumor.
Technically, the field









IMRT 6 May be appropriate
depending on the
clinical situation on a
case-by-case basis.
Enrollment in a clinical
trial preferred.
Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9
Usually appropriate.
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therapy; 1,350 patients were randomized to either
neoadjuvant short-course radiation therapy (5 x 5 Gy)
or selective postoperative concurrent chemoradiation
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patients with CRM involvement (defined as ≤1 mm)
[23]. Patients with resectable rectal cancer who received
preoperative radiation had a decreased rate of local
recurrence at 3 years compared to patients who received
adjuvant long-term radiation therapy. Together, the
CKVO 95-04 and MRC CR07 studies confirm that radia-
tion improves local control even with TME surgical
technique. Because of the toxicity of long-term radiation
treatment and the inability to safely combine the hypo-
fractionated radiotherapy regimen with systemic che-
motherapy, this approach is rarely used in the United
States or Southern Europe, but it is more common in
Northern Europe [20].
Importantly, two trials from Europe have examined
the role of incorporating concurrent chemotherapy with
preoperative irradiation using standard radiotherapy
fractionation, in keeping with the postoperative com-
bined chemoradiotherapy model. Two studies — one by
the European Organisation for Research and Treatment
of Cancer (EORTC 22921), the other by the Fondation
Francaise de Cancerologie Digestive (FFCD 9203) —
demonstrated a significant improvement in local control,
in the absence of a survival or sphincter-preservation
benefit, with the addition of chemotherapy [24,25]. As
expected, acute toxicity was increased with the addition
of chemotherapy, as had been noted in the FFCD 9203
trial [25]. (See Table 3.)
Preoperative versus postoperative chemoradiotherapy
The important question of comparing preoperative ver-
sus postoperative chemoradiotherapy, as noted above,
was addressed by a randomized trial from Germany. The
preoperative regimen, as published by Sauer et al [3],
was associated with significantly improved local control
and increased sphincter-preservation rates with no dif-
ferences in disease-free or OS. As surgical technique
continues to improve, it becomes increasingly difficult to
demonstrate a benefit in disease-free or OS. Neoadju-
vant delivery also resulted in decreased rates of acute
and chronic treatment toxicity, when compared to the
postoperative approach. Another randomized trial
(NSABP R03) exploring the same question in the United
States was terminated early due to poor accrual. This
study did not require TME, but it did show a trend
towards improved survival, with a significant improve-
ment in recurrence-free survival and disease-free survi-
val [26]. Clinical response to the preoperative therapy
was associated with significantly improved disease-free
and OS [27]. The current standard of care in the United
States is, therefore, to provide preoperative chemora-
diotherapy, using standard radiotherapy fractionation
and concurrent fluorouracil for clinical stage T3 or T4
or for node-positive rectal cancer.Simulation
Physical positioning to displace the small bowel is a sim-
ple way of maximizing the therapeutic ratio. A compara-
tive study shows that when a patient is placed prone, the
use of a belly board combined with a full bladder
reduces the volume of small bowel irradiated by 70%
(about 100 cc) [28]. Use of intensity-modulated radiation
therapy (IMRT) with supine positioning potentially obvi-
ates the geometric benefit of placing the patient in the
prone position on a belly board, which is uncomfortable
and presumably more difficult for the patient to tolerate.
A retrospective study comparing prone or supine setup
with daily image guidance versus a no-action-level pro-
tocol confirmed that prone positioning leads to a greater
systematic error. However, the study noted increased
random error with the supine position. Error was
decreased with either setup using increased frequency of
image guidance [29]. One study from the UK evaluated
prone versus supine positioning in 19 consecutive
patients and found the prone position did decrease dose
to the small bowel, but primarily only in the low dose
region of the dose-volume histogram [30]. At doses
above 20 Gy, there was no appreciable difference
between supine and prone positioning, lending support
to the notion of using the supine position in patients
who may not tolerate lying prone with a full bladder.
Timing of surgery
One of the major differences in the adjuvant trials from
Europe versus those from the United States has been
regarding the timing of surgery after chemoradiotherapy.
The short-course regimens from Europe with surgery 1
week after completing radiotherapy have not allowed
adequate time for downstaging, yet it appears that with a
longer interval from neoadjuvant therapy to surgery
downstaging may occur. In a retrospective review of
patients treated with neoadjuvant chemoradiation fol-
lowed by surgery with a time interval ≤7 weeks versus
>7 weeks, the longer interval before surgery demon-
strated an improved pCR and near-pCR rates as well as
increased disease-free survival interval [31]. A primary
concern with an extended interval from chemoradiother-
apy to surgery is that tumor clonogens are afforded time
for repopulation and potential spread. A delay to surgery
beyond 12 weeks has been investigated in selected
patients and appears to be safe without an increase in
metastatic spread [32].
Infusional versus oral 5-FU
Since the advent of oral 5-FU, capecitabine, its equiva-
lence has been called into question. A multitude of ret-
rospective data exists with conflicting results. Several
randomized phase III studies have recently been
reported that add support to the use of capecitabine.
Table 3 60-year-old woman with circumferential lesion




Preoperative RT + chemo 9
Postoperative RT + chemo 3
Preoperative RT alone 1
Postoperative RT 1
If Preoperative RT: RT Dose
45 Gy/1.8 Gy 7
50.4 Gy/1.8 Gy 9
54 Gy/1.8 Gy 7 If small bowel is
completely excluded
after 50.4 Gy.
59.4 Gy/1.8 Gy 2 If small bowel is
completely excluded
after 50.4 Gy.
For fixed lesions only.
5 Gy x 5 1
Surgery
LAR 9
APR 1 Only if LAR is not
technically possible.
If Postoperative RT: RT Dose
45 Gy/1.8 Gy 6
50.4 Gy/1.8 Gy 9
54 Gy/1.8 Gy 8 If small bowel is
completely excluded
after 50.4 Gy.
59.4 Gy/1.8 Gy 3 If small bowel is
completely excluded
after 50.4 Gy.
For fixed lesions only.
5 Gy x 5 1
Simulation
Patient prone 9 Unless physically unable.




9 Not mandated with
CT simulation.
Patient immobilized 9
Use belly board 9 Only needed if prone.
Anal marker 9
Bladder full at simulation 7
RT Technique
3 or 4 field with photons 9 Depending on clinical situation.
IMRT 6 May be appropriate depending
on the clinical situation on a
case-by-case basis. Enrollment
in a clinical trial preferred.
Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9
Usually appropriate.
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concurrent chemotherapy investigating four different
chemotherapy regimens (5-FU or oral capecitabine with
or without oxaliplatin). Preliminary results have recently
been reported and show no significant difference
between the arms with respect to pCR, sphincter pre-
servation, or downstaging. However, the addition of oxa-
laplatin was associated with a notable increase in grade
3 and 4 gastrointestinal (GI) toxicity [33]. Another ran-
domized trial of 401 patients from Germany comparing
infusional 5-FU versus oral capecitabine concurrent with
neoadjuvant radiation therapy suggests different toxicity
profiles between the two chemotherapy regimens with
less leucopenia and increased hand-foot skin reactions
associated with capecitabine. This noninferiority Ger-
man study suggests that oral capecitabine is not inferior
to infusional 5-FU, and is associated with an increased
rate of ypN0 tumors demonstrating increased downsta-
ging with the oral drug [34].
Current questions
The role of neoadjuvant chemoradiotherapy in resect-
able rectal cancer has been established, but the possibi-
lity of increasing the therapeutic gain via newer
chemotherapeutic agents exists. Two large trials, the
French ACCORD and the Italian STAR trial, both evalu-
ate the role of oxaliplatin, which increases the efficacy of
fluorouracil-based chemotherapy in treating colon can-
cer [35,36]. These trials clearly show an increase in toxi-
city with the addition of oxaliplatin with no apparent
improvement in local response. This use of oxalaplatin is
supported by the recent preliminary results from NSABP
R-04, which showed no apparent benefit with the addi-
tion of oxalaplatin to neoadjuvant concurrent chemora-
diotherapy. The use of IMRT with capecitabine and
oxaliplatin is being examined in a phase II study
(RTOGW 08-22), but the results are not yet available.
The role of biologic agents in treating rectal cancer has
not yet been established.
The role of additional adjuvant chemotherapy after
chemoradiotherapy in either the neoadjuvant or adjuvant
setting is also in question. Although it is clearly indi-
cated with colon cancer, several large trials from Europe
and a meta-analysis have failed to show any benefit.
Adjuvant chemotherapy after either neoadjuvant or
adjuvant chemoradiotherapy has remained the standard
of care based on extrapolated data from colon cancer. A
randomized trial was initiated to determine whether
additional chemotherapy is necessary in rectal cancer,
but unfortunately due to lack of clinical equipoise, the
study failed to accrue and closed early. Analysis of the
Surveillance, Epidemiology, and End Results (SEER)
database comparing patients who received adjuvant che-
motherapy with those who did not suggests that patients
Table 4 45-year-old woman with EUS staged T4N0, 4 cm
lesion at 3 cm from verge with extensive involvement of
the anal canal, KPS ≥70
Treatment Rating Comments
Treatment Options
Preoperative RT + chemo
followed by surgery






if pT3+ and/or LN+
1
If Preoperative RT: RT Dose
45 Gy/1.8 Gy 6
50.4 Gy/1.8 Gy 9
54 Gy/1.8 Gy 8 If small bowel is
completely excluded
after 50.4 Gy.
59.4 Gy/1.8 Gy 3 If small bowel is
completely excluded
after 50.4 Gy.
For fixed lesions only.
5 Gy x 5 1 Will not provide
sufficient downstaging.
Simulation




9 Not mandated with
CT simulation.
Patient immobilized 9
Use belly board 9 Only needed if prone.
Anal marker 9
Bladder full at simulation 7
If Preoperative RT: RT Volume
Pelvis to L5/S1 + boost 8
Pelvis to L5/S1 +





3 or 4 field with photons 9 Depending on
clinical situation.
AP/PA 1
3 field with electron
boost to perineum
3
4 field with electron
boost to perineum
3
IMRT 8 Using atlas for target
delineation.
Based on anal cancer data.
May be helpful to treat
inguinal lymph nodes
and to reduce side effects.
Table 4 45-year-old woman with EUS staged T4N0, 4 cm
lesion at 3 cm from verge with extensive involvement of
the anal canal, KPS ≥70 (Continued)









Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9
Usually appropriate.
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motherapy [37].
IMRT has a demonstrated benefit in the treatment of
anal malignancies, with fewer treatment breaks pre-
sumed to be due to the decreased toxicity associated
with more conformal dose delivery. The RTOGW
launched a phase II study investigating the use of IMRT
for T3-4N0-2 patients with capecitabine and oxaliplatin.
The preliminary results, presented in abstract form only,
revealed a trend towards decreased preoperative GI
grade ≥2 toxicity when compared to RTOGW 0247 [38].
A recent single-institution retrospective review compar-
ing IMRT to classic 3-field conventional radiotherapy
demonstrated a significant decrease in GI toxicity grade
≥2 for patients receiving IMRT [39]. It is the consensus
of the expert panel authoring this document that IMRT
clearly decreases toxicity in the treatment of rectal
cancer. Certain situations requiring larger treatment
volumes such as postoperative therapy after an abdo-
minoperineal resection (APR) or radiation of the ingu-
inal nodes warrants a stronger recommendation for
IMRT; however, there are concerns regarding delivery
of IMRT outside the confines of a clinical trial. IMRT
requires a greater knowledge of anatomic spread and
understanding of the surrounding normal tissues and
tolerances than the conventional 3-field pelvis treat-
ment based on bony anatomy. This difficulty in con-
touring was clearly demonstrated in RTOGW 0529
where there were a significant number of inadequately
contoured cases; however, due to a rapid review pro-
cess, corrections were made prior to patient treatment.
Multiple studies document the interobserver variability
in target delineation with highly conformal therapy,
and the need for guidance or aids in target delineation
to avoid missing critical targets [40,41]. The need for
education regarding IMRT volumes in the pelvis was
addressed by consensus panel of experts convened by
RTOGW to create an anorectal contouring atlas that
helps delineate targets [42]. The preferred delivery for
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formed outside of a clinical trial, the atlas and peer
review through colleagues or an established review
process is strongly recommended.
Patients with low-lying rectal tumors extending below
the dentate line and with extensive involvement of the
anal canal receive treatment resembling that used for
anal cancer, including treatment of the external iliac and
inguinal nodes based on patterns of lymph node drai-
nage. Retrospective data from MD Anderson Cancer
Center suggests that the inguinal spread of rectal cancer,
even with involvement of the anal canal, may be a rare
event and that prophylactic radiotherapy to the groin
may be unnecessary [43]. This study defines patients
having disease within 4 cm of the anal verge as having
involvement of the anal canal, but it does not comment
on extensive involvement with extension to the anal
verge or margin. Further validation is necessary before
omitting inguinal radiation therapy in patients with
extensive involvement of the anal canal. (See Table 4.)
Need for future trial
Despite the published data from randomized trials that
support the shift to preoperative chemoradiotherapy, a
subset of patients will require surgical resection upfront
for a variety of clinical reasons. A pooled analysis of five
randomized clinical trials in the United States suggests
that not all patients with resected tumors may require a
trimodality (surgery, chemotherapy, radiotherapy) treat-
ment approach. Patients with favorable or “intermediate-
risk” (T3N0 or T1-2N1) tumors were found to have
benefited equally from either postoperative chemora-
diotherapy or chemotherapy alone [44,45]. Other data
from the Memorial Sloan-Kettering Cancer Center
(MSKCC) suggests that understaging may be a signifi-
cant problem, as 22% of the patients in the trial who
were cT3N0 were found to be pN+ at the time of
surgery [46].
A risk-adapted approach, selecting patients for mini-
mal surgery based on their response to preoperative che-
moradiotherapy has been investigated. Preliminary
results from a recently reported small phase II trial by
the American College of Surgeons Oncology Group
(ACOSOG Z6041) suggests select patients who have a
small cT2N0 tumor may be candidates for preoperative
chemoradiotherapy followed by local excision rather
than proctectomy [47]. The possibility of deferring or
eliminating surgery for patients with a complete
response to neoadjuvant chemoradiotherapy has also
been suggested [48]. A future clinical study is warranted
to validate the appropriateness of such risk-adapted
treatment-minimization strategies.
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